Mirum Pharmaceuticals Inc logo

MIRM - Mirum Pharmaceuticals Inc Share Price

$20.44 0.2  1.2%

Last Trade - 5:09pm

Sector
Healthcare
Size
Mid Cap
Market Cap £410.6m
Enterprise Value £282.9m
Revenue £n/a
Position in Universe 2859th / 6347
Bullish
Bearish
Unlock MIRM Revenue
Momentum
Relative Strength (%)
1m +12.8%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -28.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 14.3
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Mirum Pharmaceuticals Inc revenues was not reported. Net loss increased from $6M to $21.3M. Higher net loss reflects Research and development - Balancing val increase from $4.8M to $16.3M (expense), General and administrative - Balancing v increase from $1.2M to $3.2M (expense), Stock-based Compensation in SGA increase from $147K to $1.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

MIRM Revenue Unlock MIRM Revenue

Net Income

MIRM Net Income Unlock MIRM Revenue

Normalised EPS

MIRM Normalised EPS Unlock MIRM Revenue

PE Ratio Range

MIRM PE Ratio Range Unlock MIRM Revenue

Dividend Yield Range

MIRM Dividend Yield Range Unlock MIRM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
MIRM EPS Forecasts Unlock MIRM Revenue
Profile Summary

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its focuses on diseases for which the unmet medical need is high and the biology for treatment is clear. Its pipeline consists of two clinical-stage product candidates with mechanisms of action that have potential utility across a range of orphan liver diseases. The Company initially developing maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. It has commenced enrollment in the Phase III clinical trial in PFIC and also planning to initiate a Phase III clinical trial in ALGS. The Company is developing volixibat for the treatment of adult patients with cholestatic liver diseases and expect to initiate Phase II clinical trials. In addition to data from ongoing clinical trials of maralixibat.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated May 2, 2018
Public Since July 18, 2019
No. of Shareholders: n/a
No. of Employees: 41
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 25,389,987
Free Float (0.0%)
Eligible for
ISAs
SIPPs
MIRM Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for MIRM
Upcoming Events for MIRM
Frequently Asked Questions for Mirum Pharmaceuticals Inc
What is the Mirum Pharmaceuticals Inc share price?

As of 5:09pm, shares in Mirum Pharmaceuticals Inc are trading at $20.44, giving the company a market capitalisation of £410.6m. This share price information is delayed by 15 minutes.

How has the Mirum Pharmaceuticals Inc share price performed this year?

Shares in Mirum Pharmaceuticals Inc are currently trading at $20.44 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Mirum Pharmaceuticals Inc price has moved by % over the past year.

What are the analyst and broker recommendations for Mirum Pharmaceuticals Inc?

There are no analysts currently covering Mirum Pharmaceuticals Inc.

When will Mirum Pharmaceuticals Inc next release its financial results?

Mirum Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Mirum Pharmaceuticals Inc dividend yield?

Mirum Pharmaceuticals Inc does not currently pay a dividend.

Does Mirum Pharmaceuticals Inc pay a dividend?

Mirum Pharmaceuticals Inc does not currently pay a dividend.

When does Mirum Pharmaceuticals Inc next pay dividends?

Mirum Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Mirum Pharmaceuticals Inc shares?

To buy shares in Mirum Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Mirum Pharmaceuticals Inc?

Shares in Mirum Pharmaceuticals Inc are currently trading at $20.44, giving the company a market capitalisation of £410.6m.

Where are Mirum Pharmaceuticals Inc shares listed? Where are Mirum Pharmaceuticals Inc shares listed?

Here are the trading details for Mirum Pharmaceuticals Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: MIRM
What kind of share is Mirum Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Mirum Pharmaceuticals Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Mirum Pharmaceuticals Inc share price forecast 2020?

Shares in Mirum Pharmaceuticals Inc are currently priced at $20.44. At that level they are trading at 74.11% discount to the analyst consensus target price of 0.00.

Analysts covering Mirum Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.56 for the next financial year.

How can I tell whether the Mirum Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mirum Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been 0.68%. At the current price of $20.44, shares in Mirum Pharmaceuticals Inc are trading at 39.79% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Mirum Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Mirum Pharmaceuticals Inc.

Who are the key directors of Mirum Pharmaceuticals Inc?

We were unable to find the directors for Mirum Pharmaceuticals Inc.

Who are the major shareholders of Mirum Pharmaceuticals Inc?

Here are the top five shareholders of Mirum Pharmaceuticals Inc based on the size of their shareholding:

New Enterprise Associates (NEA) Venture Capital
Percentage owned: 16.49% (4.19m shares)
Frazier Healthcare Partners Venture Capital
Percentage owned: 14.05% (3.57m shares)
Deerfield Management Company, L.P. Hedge Fund
Percentage owned: 13.58% (3.45m shares)
Novo Holdings A/S Venture Capital
Percentage owned: 9.63% (2.45m shares)
RiverVest Venture Partners, LLC Venture Capital
Percentage owned: 7.57% (1.92m shares)
Similar to MIRM
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.